Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH ombudsman’s report

This article was originally published in The Gray Sheet

Executive Summary

Number of contacts received by CDRH Ombudsman Les Weinstein in 2004 grew to 125, up from 120 in 2003, according to the 1ombudsman's annual report. Industry accounted for 90% of 2004 contacts, compared with 78% in 2003 (2"The Gray Sheet" April 5, 2004, p. 8). The Office of Device Evaluation remains the office most often involved with disputes/complaints (66%). Premarket notifications are still the most cited subject for disputes/complaints (28%), while inspections (4%) and HDEs (2%) were added to the list for the first time in 2004. Miscommunication or lack of communication continues to be the top reason for complaints/disputes (25%), followed by "least burdensome" issues (16%). By the end of 2004, about 35% of complaints/disputes were pending, 31% resolved, 21% withdrawn or not followed-up and 13% referred outside CDRH. In 2003, 26% were resolved and 22% were pending...

You may also be interested in...



Device Center Disputes And Complaints Increased In 2003 – Ombudsman

The number of complaints received by CDRH Ombudsman Les Weinstein roughly tripled last year

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel